Trials / Recruiting
RecruitingNCT05789602
A Study of BPI-460372 in Advanced Solid Tumor Patients
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-460372 in Advanced Solid Tumor Patients
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 82 (estimated)
- Sponsor
- Betta Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPI-460372 | Subjects will receive BPI-460372 until disease progression |
Timeline
- Start date
- 2023-04-24
- Primary completion
- 2025-04-17
- Completion
- 2026-04-17
- First posted
- 2023-03-29
- Last updated
- 2025-01-27
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05789602. Inclusion in this directory is not an endorsement.